• Skip to primary navigation
  • Skip to main content
Butchertown Clinical Trials

Butchertown Clinical Trials

Paid Clinical Trials in Louisville, KY

  • Blog
  • Patients
    • Currently Enrolling Clinical Trials
    • Process
    • FAQs
  • Partners
    • Physicians
    • Sponsors and CROs
    • Become a Physician Partner
    • Facility, Equipment, and Capabilities
  • About
    • Contact
    • Research Team
    • Dry Eye Research and Clinical Trials
    • Diversity, Equity, and Inclusion
    • Leave a Review
  • Show Search
Hide Search

Press Releases

Alcon Gains FDA Approval of TRYPTYR® Eye Drops for the Treatment of Signs and Symptoms of Dry Eye Disease Marking the 23rd FDA Approval for Butchertown Clinical Trials

Mark Prussian · May 28, 2025 ·

May 28, 2025

Alcon announced the U.S. Food and Drug Administration (FDA) approved TRYPTYR® (acoltremon ophthalmic solution) 0,003%, formerly known as AR-15512, for the treatment of signs and symptoms of Dry Eye Disease.

“In clinical trials, I found the mechanism of action of this novel eye drop to be highly effective in stimulating TRPM8 receptors, which leads to reducing corneal pain while also increasing the eye’s natural tear production. I am honored to have worked on multiple clinical trials to help this new eye drop gain FDA approval, so it is available to my patients, and all dry eye sufferers”, said Guru R. Pattar, MD, PhD, Principal Investigator.

The eye drop will be available by prescription in single-use vials, one drop per eye, two times a day. It is expected to be available by the fall of 2025.

“This marks our 23rd FDA approval. Along with our sponsoring scientific research partners, including those in the pharmaceutical and biotechnology space, we have several new treatments pending before the FDA so there are many more announcements to come, as we are pleased to continue to offer new treatment options and to help improve human health through our Louisville, KY-based clinical trials site, Butchertown Clinical Trials,” said Mark Prussian, CEO and co-founder.

Butchertown Clinical Trials is an affiliate of The Eye Care Institute.

tryptyr logo

Bausch + Lomb Gains FDA Approval of LUMIFY® Preservative Free Redness Reliever Eye Drops, Marking the 22nd FDA Approval For Butchertown Clinical Trials

Mark Prussian · April 17, 2025 ·

Bausch + Lomb Corporation announced, during April 2024,  the U.S. Food and Drug Administration (FDA) approved LUMIFY® Preservative Free redness reliever eye drops, the first and only over-the-counter preservative-free eye drop with low-dose OTC brimonidine tartrate for the treatment of ocular redness due to minor eye irritations.

“LUMIFY Preservative Free significantly reduces redness within one minute and lasts up to eight hours,” said John Ferris, executive vice president, Consumer, Bausch + Lomb.

Now available, this over-the-counter (OTC) eyedrop underwent clinical trials at Butchertown Clinical Trials, with Dr. Guruprasad R. Pattar, MD, PhD of The Eye Care Institute as the Principal Investigator.

Although OTC products do not necessarily have to undergo strict clinical trial protocols, nor is FDA approval typically required, this product did so as it contains a small quantity of a prescription medication called brimonidine tartrate, most often used to treat open angle glaucoma or ocular hypertension. In the small quantity used in Lumify PF .025%, brimonidine tartrate acts to relieve ocular redness. With the addition of Lumify PF .025% I have the confidence to strongly recommend this OTC product to my patients seeking relief from red eyes, said Dr. Emily Ebelhar, OD, also of The Eye Care Institute, who served as Sub Investigator. This marks the 22nd FDA approval for Butchertown Clinical Trials, an affiliate of The Eye Care Institute.

drop

We Have Been Named a Top Workplace in Kentucky

Mark Prussian · March 7, 2025 ·

The Eye Care Institute, and our sister company, Butchertown Clinical Trials, proudly announce that we have been named a Top Workplace in Kentucky by the Kentucky Chamber of Commerce and Workforce Research Group.

best places

“Our ‘We Are The Yes Practice’ model emphasizes meeting patient expectations and offers a superior working environment to our employees. This is best achieved when patient needs are addressed first, without sacrificing our staff’s best interest,” said Mark Prussian, CEO of The Eye Care Institute and Butchertown Clinical Trials. “The ‘Yes Practice’ model stresses patient and staff well-being. It offers our doctors career satisfaction and motivates their ability to provide excellent patient care.”

“The varying backgrounds and experiences of our staff strengthen us as a healthcare organization. Therefore, we commit to always hiring the best candidate for each open position. Employing well-rounded people, offering fair pay and benefits, meeting the work/life needs of our staff, and providing continuous training results in our staff having a sense of pride in their workplaces, and this results in a better patient experience,” Prussian continued.

The inclusion of The Eye Care Institute and Butchertown Clinical Trials as a Top Workplace reflects our ongoing dedication to staff contentment and consistent efforts to improve the workplace experience. “We believe patients of The Eye Care Institute are well-served by these commitments, as we have nearly 2,000 5-star Google reviews,” Prussian said.

Butchertown Clinical Trials and The Eye Care Institute Announce 21st FDA Approval

Mark Prussian · March 14, 2024 ·

LOUISVILLE, KENTUCKY, UNITED STATES, March 11, 2024 /EINPresswire.com/ — Formosa Pharmaceuticals, Inc., Songshan Dist., Taipei City 105, Taiwan, announced the U.S. Food and Drug Administration (FDA) approved Clobetasol propionate ophthalmic suspension, 0.05% (APP13007) for the treatment of ocular inflammation and pain following ocular surgery.

Dr. Brennan P. Greene, MD. continued “Although much work remains to eradicate post-operative pain and inflammation, this is another good choice for treating some of the seven million people per year who undergo eye surgery in the United States.”

Clobetasol propionate ophthalmic suspension is another excellent addition to the family of medicines that help treat inflammation and pain following eye surgery.”

— Dr. Brennan Greene, Principal Investigator

Mark Prussian, CEO of Butchertown Clinical Trials, said, “I find it especially gratifying when research institutions affiliate to create a drug such as this. In this case, Formosa is working with our previous clinical trial partner, Eyenovia, to market and commercialize the drug, which is also a development partner with Senju, with whom we have also partnered on other clinical trials.”

This is the 21st FDA-approved drug or device for Louisville, KY-based Butchertown Clinical Trials, a division of The Eye Care Institute. Mark Prussian stated each FDA approval is a breakthrough for medicine and for the improvement of the lives of our patients.

# # #

For more information:

Mark Prussian
Butchertown Clinical Trials

+1 502-589-1500
email us here

Visit us on social media:

  • Facebook
  • Twitter
  • LinkedIn
  • Instagram

Butchertown Clinical Trials and The Eye Care Institute Announce Our 20th FDA Approval Qlosi™, an Eyedrop for the Treatment of Presbyopia

Mark Prussian · October 18, 2023 ·

Orasis Pharmaceuticals Announces FDA Approval of QLOSI™

(pilocarpine hydrochloride ophthalmic solution) 0.4% for the Treatment of Presbyopia

Ponte Vedra, FL, October 18, 2023

QLOSI (pronounced CLOH-see) is a prescription eye drop that can be used daily or as needed, up to twice per day. QLOSI demonstrated efficacy 20 minutes after administration and can last up to 8 hours.

John C. Meyer, MD, of The Eye Care Institute and Butchertown Clinical Trials, was the Principal Investigator. Dr. Meyer stated that many presbyopia treatments are available, including glasses, contact lenses, LASIK laser vision correction, and cataract surgery with intraocular lens implants. The availability of an eye drop will be right for patients who wish to improve their vision without needing glasses, contact lenses, or various types of surgery.

This is the 20th FDA approved drug or device for Louisville, KY-based Butchertown Clinical Trials, a division of The Eye Care Institute. Mark Prussian stated each FDA approval is a breakthrough for medicine and for the improvement of the lives of our patients. More treatment options result in a better quality of life for those with this refractive error.”

  • Go to page 1
  • Go to page 2
  • Go to Next Page »
best places

Butchertown Clinical Trials
205 N. Spring Street
Louisville, KY 40206

502-219-7700
Mon-Fri, 8am – 5pm

Contact Us

bct logo

Butchertown Clinical Trials is an Ophthalmic, Vaccine, Adult Medicine and Metabolic Disease Clinical Trials Research Site in Louisville, KY

eci logo

Our parent company, The Eye Care Institute, are Leaders in LASIK ® and multiple other ways to improve your vision

bbb

Copyright © 2025 · Butchertown Clinical Trials, All Rights Reserved

Website designed and supported by Louisville Web Nerds